Register Login
Register to leave comments
  • News bot Oct. 30, 2025, 12:32 p.m.

    📋 Ultragenyx Pharmaceutical Inc. (RARE) - Clinical Trial Update

    Filing Date: 2025-10-30

    Accepted: 2025-10-30 08:30:24

    Event Type: Clinical Trial Update

    Event Details:

    Ultragenyx Pharmaceutical Inc (RARE) Announces Clinical Trial Update Ultragenyx Pharmaceutical Inc (RARE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Collaboration: Common Stock
    • Updated Timeline: October 30, 2025
      • expected in the second half of 2026

    🔬 Clinical Development Pipeline (Ultragenyx Pharmaceutical Inc.):

    Product Type Development Stage Therapeutic Area Source
    No Investigational Product OTHER Phase PHASE3 Mucopolysaccharidosis IIIA ClinicalTrials.gov
    GTX-102 DRUG Phase PHASE3 Angelman Syndrome ClinicalTrials.gov
    Adjuvant Immunomodulatory (IM) Therapy DRUG Phase PHASE3 Mucopolysaccharidosis IIIA ClinicalTrials.gov
    No Intervention OTHER Preclinical Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) ClinicalTrials.gov
    Sodium Acetate DRUG Phase PHASE3 OTC Deficiency ClinicalTrials.gov
    Placebo for oral corticosteroids DRUG Phase PHASE3 OTC Deficiency ClinicalTrials.gov
    Oral Corticosteroids DRUG Phase PHASE3 OTC Deficiency ClinicalTrials.gov
    Placebo OTHER Phase PHASE3 OTC Deficiency ClinicalTrials.gov
    DTX301 GENETIC Phase PHASE3 OTC Deficiency ClinicalTrials.gov
    BAY2599023 (DTX201) DRUG Phase PHASE1 Hemophilia A ClinicalTrials.gov
    GLUT1 DS DRUG Phase PHASE2 Glut1 Deficiency Syndrome ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Ultragenyx Pharmaceutical Inc
    • CIK: 0001515673
    • Ticker Symbol: RARE
    • Period End Date: 2025-10-30
    • Document Type: 8-K

Search

News categories